Description: Many companies are facing challenges with their inforce UL business. These “distressed” or non-core blocks of business can be a drag on earnings, return on capital, and/or internal resources. With the pressures of today's marketplace, companies are seeking efficient strategies for managing these blocks. The good news is that strategies exist such that inforce UL business can be optimized with some attention. Learn about some options and levers companies have available to help manage these blocks.

Description: This session will kick off the key National Association of Insurance Commissioners (NAIC) activities with a primary focus on updates to principle-based reserve valuations and appointed actuary topics. Hear insights into the current set of activities and initiatives being considered and/or adopted by the NAIC Life Actuarial Task Force (LATF) and the NAIC Risk Based Capital Working Group as well as Actuarial Standards Board. In addition, other actuarial practice issues and other appointed actuary and opinion topics relevant to life insurance, variable annuities and fixed annuities will be discussed. By the end of the session, attendees will understand what changes are being made to reserves, RBC, PBR and actuarial standards and related topics, and the anticipated timing of such emerging changes.

Description: Join us for this popular annual webcast covering the latest considerations for the year's U.S. statutory financial reporting work. Get ready to hear from three expert speakers, who will discuss cash flow testing and this year’s New York and California holiday letters, the impact of recent interest rate changes including treatment of negative IMR, potential changes to statutory financial reporting due to climate change, and updates regarding Principle Based Reserves.

Description: There are a variety of regulatory changes that are being contemplated by the National Association of Insurance Commissioners (NAIC) that have the potential to materially impact actuarial, statutory reporting and disclosure requirements relating to reinsurance. This session will provide an introduction to these changes, explaining both the motivation as well as the potential impact these proposed changes may have on US ceding companies. The focus of the presentation will be primarily on changes affecting Asset Adequacy Testing and statutory risk transfer for combination Coinsurance / Yearly Renewable Term agreements. An update will be provided regarding industry responses to proposed changes and the potential timing for implementation of these new requirements.

Description: You’ve written the position papers, updated the models, and designed the required disclosures, but you may be wondering how to explain the results during interim financial reporting periods to company management as well as other stakeholders. This session will explore ways to adapt existing management reporting and offer ideas for new metrics. We will explore various methods for analyzing DAC amortization patterns, market risk benefit reserve patterns, and Liability for Future Benefits (LFPB) movements. In addition, this session will explore ways to integrate changes in LDTI with business planning and other broader business issues such as product pricing considerations and reinsurance strategy.

Description: There are a number of ways insurers can deploy their capital. Lately the chase for yield, the need for long-tailed risk optimization, and a refocusing on core competencies have driven recent capital trends in the industry. M&A activity has been hot lately, private equity firms have grown their involvement in the industry, and insurers have continued to innovate in their funding of new business strain and investment into customer experience. In this session we will discuss these trends as we study insurer capital optimization through M&A, offshore, and structured reinsurance.

Description: What if a blood test can detect more than 50 types of cancer, including those in early stages? A biotech company, GRAIL, has developed the first-to-market Multi-Cancer Early Detection test and launched it for commercial use in 2021. Join us to learn how Munich Re and GRAIL are partnering to bring its Galleri test to the life insurance industry. You will also explore how we as an industry can help save lives by detecting cancer earlier and share perspectives on some early findings and cost-benefit analysis